The company will also highlight its sustainability strategies and quality solutions at the event.

The European Union aims to become the most attractive place for life science by 2030.

Life sciences CEOs are boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development.

Data from four major pivotal trials will be shared, but AstraZeneca medications and pipeline molecules appear in more than 90 abstracts for the upcoming conference in Berlin.

This issue showcases strategies that organizations are adopting to stay competitive as pressing industry trends shape the sector.

This paper provides an in-depth overview of the anatomical structure and functional dynamics of renal filtration, secretion, and reabsorption processes that govern drug clearance.

US President Donald Trump made the announcement that AstraZeneca is the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.

Pharma accelerates specialized R&D and clinical pipelines via agentic AI and collaboration, while manufacturing scales through CGT 2.0 flexibility, automation, and digitized supply chain security.

AstraZeneca’s $4.5 billion investment in Virginia expands its US drug manufacturing footprint, creating 3600 jobs and integrating AI for cancer and metabolic therapies.

The new label for prefilled syringes, in conjunction with innovations from SCHOTT Pharma, enables integrated tamper-evidence and digital tracking across the supply chain.

At the Cell and Gene Meeting on the Mesa, a panel discussion was held on advanced therapy production and how it demands modular platforms, automation, and data governance to drastically improve patient access and affordability.

The awarded $1.7 million in funding will support the company’s preclinical and clinical progress on DMX-1001 (noribogaine), designed to reduce relapse and improve brain health in patients with alcohol use disorder.

The growing demand for liquid medicines is increasingly driven by the unique needs of several distinct patient groups, improving compliance in these demographics through flexible, palatable dosing options.

The licensing of Talicia, an FDA-approved fixed-dose therapy, to key at-risk markets strategically combats an increasingly high antibiotic resistance to the cancer-causing bacteria.

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.

Artificial intelligence and machine learning are anticipated to boost success rates.

Artificial intelligence, machine learning, and novel instruments are helping drug developers evaluate complex data from bioanalytical studies.

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

Siegfried Schmitt, PhD, vice-president, Technical at Parexel, answers questions on the use and benefits of real-world evidence for small-molecule and large-molecule drug development.

Pharma news on AI's role in drug development, new FDA/EMA guidance, clinical advances, MFN pricing agreements, and ongoing quality control challenges.

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging, at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.

Pfizer re-balances weight loss portfolio with Metsera, Bristol Myers Squibb and Roche make breast cancer progress, and Keytruda gets under your skin.

This article takes a look at the developing use of AI in pharmaceutical development and manufacturing.

The go-ahead for Novartis’ oral treatment marks a new option for patients with spontaneous urticaria who remain symptomatic despite antihistamine therapy.

This review of the nitrosamines contamination problem in pharmaceuticals takes a look at how the crisis started and developed.

Sept. 30 marked 61 days since July 31, one day past the timeframe President Donald Trump had set forth for companies to lower prescription drug prices in the United States.

A draft reflection paper on patient experience data is up for public consultation until Jan. 31, 2026.

FDA's Center for Biologics Evaluation and Research has released updated draft recommendations for sponsors of cell therapies, gene therapies, and tissue products.